C3N-00293
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 73.30321697
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.200
- HEDGEHOG_SIGNALING+0.180
- NOTCH_SIGNALING+0.170
- WNT_BETA_CATENIN_SIGNALING+0.100
- TGF_BETA_SIGNALING+0.080
- KRAS_SIGNALING_DN+0.070
- BILE_ACID_METABOLISM+0.060
- UV_RESPONSE_DN+0.060
- PANCREAS_BETA_CELLS+0.040
- APICAL_JUNCTION+0.020
Top 10 suppressed
- E2F_TARGETS-0.650
- MTORC1_SIGNALING-0.590
- MYC_TARGETS_V1-0.590
- OXIDATIVE_PHOSPHORYLATION-0.570
- G2M_CHECKPOINT-0.530
- UNFOLDED_PROTEIN_RESPONSE-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- MYC_TARGETS_V2-0.450
- TNFA_SIGNALING_VIA_NFKB-0.420
- HYPOXIA-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8526730 | — | cohortA1 | 0.915 |
| 2 | TCGA-55-8097-01A-11R-2241-07 | — | cohortA1 | 0.911 |
| 3 | b03ebc32.a177.44c7.8b02.fcd6560712f2 | — | cohortA1 | 0.904 |
| 4 | TCGA-CU-A3YL-01A-11R-A22U-07 | — | — | 0.903 |
| 5 | C3N-02950 | — | cohortA1 | 0.900 |
| 6 | TCGA-NJ-A55A-01A-11R-A262-07 | — | cohortA1 | 0.898 |
| 7 | SRR6013544 | — | cohortA1 | 0.896 |
| 8 | d2995480-5ae0-42e1-9a21-25e1435201ee | — | — | 0.892 |
| 9 | X698ec707.1965.46b2.81ff.3c3445a68d1a | — | cohortA1 | 0.890 |
| 10 | SRR1313120 | — | A | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.060 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.040 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |